Last reviewed · How we verify

NCT03515421

Project Frazier 3 Regulatory Clinical Evaluation

Completed NA Last updated 10 September 2020
What this trial tests

NA trial testing Frazier 3 Verio in Diabetes Mellitus in 379 participants. Completed in 18 June 2018.

Timeline
9 April 2018
Primary endpoint
18 June 2018
18 June 2018

Quick facts

Lead sponsorLifeScan Scotland Ltd
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment379
Start date9 April 2018
Primary completion18 June 2018
Estimated completion18 June 2018
Sites4 locations across United Kingdom, Germany

Drugs / interventions tested

Conditions studied

Sponsor

LifeScan Scotland Ltd

Who can join

12 and older, any sex, with Diabetes Mellitus or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical Evaluation of Blood Glucose Monitoring Systems (BGMSs)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other LifeScan Scotland Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing